BlackRock and Nextech betting on radiopharma with ITM

ITM supplies Novartis with an agent for its Pluvicto radiopharmaceutical, which reached sales of $211m in the first quarter.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this